Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quigley's Cold-Eeze

This article was originally published in The Tan Sheet

Executive Summary

Zinc lozenge marketer plans to have its flagship product "available in the U.K. market and the rest of the EU to follow as a full-blown pharmacy drug," President and CEO Guy Quigley says during a Dec. 7 conference call. Quigley notes the company has just completed a double-blind study, which it regards as the final step in its filing with the U.K. Medicines Control Agency. The launch would mark a shift from homeopathy for the firm. The conference call was held to clarify the terms of the company's recent consent agreement with the FTC (1"The Tan Sheet" Nov. 29, p. 11). Quigley notes the settlement does not prohibit the firm from making claims concerning the duration or severity of the common cold and says the only packaging changes that need to be made involve Sugar-free Cold-Eeze

You may also be interested in...



Quigley, QVC Cold-Eeze "Unsubstantiated Claims" Targeted By FTC

Quigley Corporation, manufacturer and marketer of the homeopathic Cold-Eeze line of zinc lozenges, and QVC Inc., a television retailing service, have agreed to settle charges they made unsubstantiated claims regarding the product's ability to "prevent colds and alleviate allergy symptoms," the Federal Trade Commission announced Nov. 23.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS090682

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel